Article Text

Download PDFPDF
Response to eLetter: ‘Discussion of methotrexate dosage’ by Maguire et al
  1. Mary Safy,
  2. J W G Jacobs,
  3. Nicole D Ijff,
  4. J W J Bijlsma,
  5. J M van Laar,
  6. Maria J H de Hair
  7. Society for Rheumatology Research Utrecht (SRU)
  1. Department of Rheumatology and Clinical Immunology, University Medical Center, Utrecht, the Netherlands
  1. Correspondence to Mary Safy, Department of Rheumatology and Clinical Immunology, F.02.127, University Medical Center Utrecht, Box 85500, 3508 GA, Utrecht, the Netherlands; m.safy{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In their letter to the editor ‘Discussion of Methotrexate Dosage’, Maguire et al 1 raised three issues regarding our recent paper.2 We appreciate their interest in our study and will address these issues here.

First, regarding the methotrexate dosage, we reiterate what we have discussed in the discussion section of our paper: ‘As in the post-trial follow-up period, the controlled situation was lost and treatment was open to the rheumatologists, long-term outcomes in our study may have been influenced by the use of different antirheumatic drugs’. We did not …

View Full Text


  • Competing interests JMvL received honoraria from MSD, Roche, Pfizer, BMS, Eli Lilly. JWJB received honoraria from AbbVie, BMS, MSD, Pfizer, Roche, SUN, UCB. MS was supported by a research grant from Astra Zeneca. Astra Zeneca was not involved in this study.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Correspondence
    Sinead A Maguire Claire Marie Sheehy